SD‐OCT‐based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti‐VEGF therapy
Acta Ophthalmologica · 2026
DOI: 10.1111/aos.17574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Ophthalmologica, 2026. Verfasst von Ken K Tsang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Hauptthemen laut MEDLINE: Tomography, Optical Coherence, Retinal Vein Occlusion, Macular Edema, Visual Acuity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To investigate the role of spectral domain optical coherence tomography (SD‐OCT)‐based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti‐vascular endothelial growth factor (VEGF) therapy.
Methods
Retrospective cohort study including consecutive cases of RVO associated MO who received anti‐VEGF injections between January 2020 and April 2021. LogMAR visual acuity (VA) at baseline, 12 and 24 months was correlated with a panel of SD‐OCT‐based biomarkers, including vitreomacular status, size of intra‐retinal cysts (IRC), presence of disorganization of retinal inner layers (DRIL), hyper‐reflective foci (HRF) in the retina, integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), cone outer segment tip (COST) and presence of subretinal fluid (SRF).
Results
One hundred and thirty eyes were included with 81 and 49 eyes in the BRVO and CRVO subgroup, respectively. In both subgroups, baseline disrupted EZ/ELM [BRVO: ( β = 0.144 p = 0.008; β = 0.111 p = 0.014; β = 0.096 p = 0.042) and CRVO: ( β = 0.316 p < 0.001; β = 0.336 p < 0.001; β = 0.327 p < 0.001)] were associated with worse VA from baseline through 24 months. In the BRVO subgroup, the presence of HRF ( β = 0.209 p < 0.001) correlated with worse baseline VA. Improvement in DRIL extent [OR = 4.355 (1.109–17.094) p = 0.035; OR = 4.510 (1.707–11.917) p = 0.002] and EZ/ELM integrity [OR = 4.474 (1.783–11.223) p = 0.001; OR = 3.214 (1.414–7.305) p = 0.005] were associated with a higher likelihood of achieving at least a 5 letters gain at 12 and 24 months.
Conclusion
A comprehensive system of SD‐OCT‐based features could predict functional outcomes of MO secondary to RVO with anti‐VEGF therapy up to 24 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
- Hong Kong Eye Hospital, Hong Kong Special Administrative Region, China.
- 2010 Eye & Cataract Centre, Hong Kong Special Administrative Region, China.
- Pao So Kok Macular Disease Treatment and Research Centre, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
ORCID-Profile: Ken K Tsang, Ziqi Tang, Dawei Yang, Truong X Nguyen, Timothy Y Y Lai, Carol Y Cheung, Simon K H Szeto
Zitieren
APA
Tsang, K. K., Hui, V. W. K., Pang, C. M. K., Tang, Z., Yang, D., Nguyen, T. X., Mohamed, S., Lai, T. Y. Y., Cheung, C. Y., & Szeto, S. K. H. (2026). SD‐OCT‐based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti‐VEGF therapy. Acta Ophthalmologica. https://doi.org/10.1111/aos.17574
Vancouver
Tsang KK, Hui VWK, Pang CMK, Tang Z, Yang D, Nguyen TX, et al. SD‐OCT‐based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti‐VEGF therapy. Acta Ophthalmologica. 2026. doi:10.1111/aos.17574
BibTeX
@article{Tsang2026,
author = {Tsang, Ken K and Hui, Vivian W K and Pang, Christopher M K and Tang, Ziqi and Yang, Dawei and Nguyen, Truong X and Mohamed, Shaheeda and Lai, Timothy Y Y and Cheung, Carol Y and Szeto, Simon K H},
title = {SD‐OCT‐based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti‐VEGF therapy},
journal = {Acta Ophthalmologica},
year = {2026},
doi = {10.1111/aos.17574}
}
EUVIMED